FDA's Michael Friedman named "lead deputy" commissioner.
This article was originally published in The Tan Sheet
Executive Summary
FDA DEPUTY COMMISSIONER FRIEDMAN WILL BE DE FACTO ACTING COMMISSIONER, assuming the duties of commissioner when David Kessler departs the agency in late February. Deputy Commissioner for Operations Michael Friedman, MD, will not be given the formal title of acting commissioner. Instead, he has been named "lead deputy commissioner, in which capacity he will perform the duties of commissioner when I depart," Kessler told FDA staff in a Jan. 30 memo. "This is necessary because the current FDA organizational structure provides no line of succession when the position of commissioner...becomes vacant," Kessler explained.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning